Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology (C1)

Scientific Organizers: Mark Mercola, Fabien Vincent, Monica Schenone and Arsenio Nueda


March 3—7, 2019

Beaver Run Resort, Breckenridge, Colorado, USA


Sponsored by Merck & Co., Inc. and Pfizer Inc.


Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: Oct 30, 2018 [details]
Discounted Abstract Deadline: Oct 30, 2018 [details]
Abstract Deadline: Dec 4, 2018 [details]
Discounted Registration Deadline: Jan 11, 2019 [details]

If you have missed a deadline due to the US government shutdown, please contact our office.

Click here to view Cancellation Policy

Register Yourself Deadlines and Fees

Rates and Deadlines listed below are for the 2019-C1 "Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology" conference only.

*All deadlines end at 11:59 PM US Mountain Standard Time

Deadline Date Cost
Discounted Abstract Deadline
More details
Before and On October 30, 2018 100.00 USD*
- 50.00 USD discount
Abstract Deadline
More details
After October 30, 2018 until January 20, 2019 100.00 USD*
* 50.00 USD of Abstract fee deducted from your registration fee when you register for this meeting
Scholarship
More details
October 30, 2018 n/a
Discounted NON-STUDENT Registration
More details
Before and On January 11, 2019 845.00 USD
(includes 200.00 discount)
Regular NON-STUDENT Registration
More details
After January 11, 2019 1045.00 USD
Discounted STUDENT Registration
More details
Before and On January 11, 2019 620.00 USD
(includes 200.00 discount)
Regular STUDENT Registration
More details
After January 11, 2019 820.00 USD

* Changes in payment type that result in a refund are subject to a processing fee.
* Currency exchange gains/losses are the responsibility of the registrant and the Keystone Symposia will accept no liability for money loss through bank charges, transfers or currency fluctuations.




Discounted Abstract Deadline: October 30, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time

Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is December 4, 2018)

Global Health Travel Award Deadline:

*All deadlines end at 11:59 PM US Mountain Standard Time


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: October 30, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: December 4, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:

  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is October 30, 2018)

Discounted Registration Deadline: January 11, 2019

*All deadlines end at 11:59 PM US Mountain Standard Time


Registration Fee: 845.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 1045.00 USD*
Student Registration Fee: 820.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that some meeting participants have received calls and emails from a number of different housing services, including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a lodging reservation with them.

We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, March 3 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 7 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 8 in order to fully experience the meeting.

SUNDAY, MARCH 3

16:00—20:00
Arrival and Registration

Colorado Ballroom Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Colorado Ballroom Foyer

MONDAY, MARCH 4

07:00—08:00
Breakfast

Summit Gallery
08:00—09:15
Welcoming Remarks and Keynote Address
Registered attendees can view abstracts starting on 02/03/2019
Big picture view of pharmaceutical development, challenges and new opportunities.

Colorado Ballroom
* Mark Mercola, Stanford University, USA

James E. Bradner, Novartis Institutes for BioMedical Research, USA
Phenotype to Chemotype to Phenotype

09:15—11:15
Clinical Success Stories
Registered attendees can view abstracts starting on 02/03/2019
Share success stories – newly approved drugs and late stage clinical candidates. Identify key lessons and best practices to inform future PDD projects.

Colorado Ballroom
* Tom Large, Blue Oak Pharmaceuticals, USA

Yoshihiro Watanabe, Kanazawa University, Japan
Discovery of Trametinib as a MEK-Inhibitor Able to Alter Phosphorylation State of MEK

Coffee Break

Fred Van Goor, Vertex Pharmaceuticals Incorporated, USA
Combination Pharmacology to Treat the Underlying Cause of the Majority of People with Cystic Fibrosis

John Tallarico, Novartis Institutes for BioMedical Research, USA
Novel Therapies from Phenotypic Screening

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
14:30—15:15
Workshop: Safety De-Risking

Colorado Ballroom
Gerhard Ecker, University of Vienna, Austria
Semantically Integrated Life Science Data – The Power of Workflows for Analysis of Phenotypic Screening Data, Toxicological Read-Across, and Repurposing

Ellen L. Berg, Eurofins DiscoverX, USA
Phenotypic Profiling for Toxicity-Associated Signatures Applied to ToxCast Chemicals

* Fabien Vincent, Pfizer Inc., USA
Safety De-Risking in Phenotypic Drug Discovery: Considerations and Strategies

15:15—16:30
Panel Discussion

Colorado Ballroom
Ellen L. Berg, Eurofins DiscoverX, USA

Neil O. Carragher, University of Edinburgh, Scotland

Chun-wa Chung, GlaxoSmithKline, UK

Tom Large, Blue Oak Pharmaceuticals, USA

Fred Van Goor, Vertex Pharmaceuticals Incorporated, USA

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
New Opportunities and Under-Represented Indications
Registered attendees can view abstracts starting on 02/03/2019
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.

Colorado Ballroom
* Jonathan A. Lee, PDD4Patients LLC, USA

Lucienne V. Ronco, Fulcrum Therapeutics, USA
Identification of FTX-1821 a Molecule that Inhibits DUX4 Expression and Rescues FSHD Pathophysiology in FSHD Skeletal Muscle Myotubes

Clemens R. Scherzer, Harvard Medical School, USA
Turning Bits and Base Pairs into Precision Neurology

Scott S. Walker, Merck & Co., Inc., USA
Large-Scale Antibacterial Phenotypic Screening and Systematic Hit Triage Reveal Novel Targets and Novel Inhibitors of Established Targets

Eachan Oliver Johnson, Broad Institute, USA
Short Talk: Large-Scale Chemical-Genetic Interaction Profiling Yields New Classes of Inhibitors of Mycobacterium tuberculosis

Patrick W. Faloon, Biogen, USA
Short Talk: Identification of Small Molecules that Increase Productive Cellular Processing of Antisense Oligonucleotides (ASOs)

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 1

Breckenridge Ballroom

TUESDAY, MARCH 5

07:00—08:00
Breakfast

Summit Gallery
08:00—11:15
Chemical Biology and Novel Molecular Mechanisms of Action
Registered attendees can view abstracts starting on 02/03/2019
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.

Colorado Ballroom
* Susanne Swalley, Biogen, USA

Maurizio Pellecchia, University of California, Riverside, USA
NMR-Based Fragment Screening for Oncology

Laura L. Kiessling, Massachusetts Institute of Technology, USA
Glycans in Health and Disease

Coffee Break

Razvan L. Cornea, University of Minnesota, USA
Targeting the Pathological Leak of a Calcium Channel for Heart Failure Therapeutics

Monica Schenone, Pfizer Inc., USA
Identification of p300/CBP as the Cellular Target of the Small Molecule “BRD16” Following a Phenotypic Screen

Sannah Zoffmann, F. Hoffmann-La Roche Ltd., Switzerland
Short Talk: Machine Learning-Powered Antibiotics Phenotypic Drug Discovery

Jean-Philippe Coppe, University of California, San Francisco, USA
Short Talk: Mapping Phospho-Catalytic Dependencies of Therapy-Resistant Tumors Reveals New Actionable Vulnerabilities

Julien Olivet, Dana-Farber Cancer Institute, USA
Short Talk: Systematic Assessment of Druggable Cavities in a Histone Deacetylase Complex

11:15—12:15
Panel Discussion: Comparing/Contrasting the Practice of PDD
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining “buy-in” from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.

Colorado Ballroom
* Jonathan A. Lee, PDD4Patients LLC, USA

Neil O. Carragher, University of Edinburgh, Scotland

Bruce Posner, University of Texas Southwestern Medical Center, USA

Veronica Soloveva, Merck, USA

Bridget Wagner, Broad Institute, USA

Guillermo Vela, NeuScience, USA

Arsenio Nueda, Almirall S.A., Spain

Christophe Antczak, Novartis Institutes for BioMedical Research, USA

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Project Prosecution and Pre-Clinical Advancement
Registered attendees can view abstracts starting on 02/03/2019
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.

Colorado Ballroom
* Scott Wolkenberg, Merck and Co., Inc., USA

Arsenio Nueda, Almirall S.A., Spain
Harnessing the Power of Phenotypic Screening to Generate Novel Starting Points for Drug Discovery

Chun-wa Chung, GlaxoSmithKline, UK
Linking Differential Molecular Mode of Action to Distinct Pharmacology

Derek Lowe, Novartis Institutes for BioMedical Research, USA
Advancement of Phenotypic Hits

Hassan Javanbakht, Gilead Sciences, USA
Short Talk: Phenotypic Screening in Antiviral Research

Hassan Al-Ali, University of Miami, USA
Short Talk: Re-Thinking Drug Target Identification and Exploiting Polypharmacology

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 2

Breckenridge Ballroom

WEDNESDAY, MARCH 6

07:00—08:00
Breakfast

Summit Gallery
08:00—11:00
Physiologically Complex and Realistic Disease Assays
Registered attendees can view abstracts starting on 02/03/2019
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.

Colorado Ballroom
* Tao Zhong, School of Life Sciences, East China Normal University, China

Randall T. Peterson, University of Utah, USA
Zebrafish Behaviors as Phenotypes for Neuroactive Compound Discovery

Mark Mercola, Stanford University, USA
High-Throughput Kinetic Studies of iPSC-Derived Cardiomyocytes: Bringing the Patient to the Early Stages of Drug Discovery

Coffee Break

Neil O. Carragher, University of Edinburgh, Scotland
Advances in Phenotypic Screening: Accelerating the Discovery of New Chemical Entities and Drug Combinations towards in vivo Proof-of-Concept

Kristin Rockwell, Pfizer, USA
Short Talk: Functional Genomics Screening in Primary Human T Cells to Identify Novel Targets for Autoimmune Diseases

Alexandre R. Colas, Sanford-Burnham Medical Research Institute, USA
Short Talk: Novel Single Cell and High-Throughput Phenotypical Platform to Study Atrial Rhythm in hPSCs

11:00—17:00
On Own for Lunch

14:30—15:30
Workshop: Clinical, Regulatory Case Studies with PDD Project Prosecution

Colorado Ballroom
* Marco Prunotto, F. Hoffmann-La Roche Ltd., Switzerland

Yevgeny Berdichevsky, Lehigh University, USA
Screen in Organotypic Hippocampal Model of Drug-Resistant Epilepsy Reveals Novel Anticonvulsants

Herve Tiriac, University of California, San Diego, USA
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Kerry L. Spear, Blue Oak Pharmaceuticals, USA
Next Generation of Drugs for Bipolar Depression: A Systems Biology Approach

15:30—16:30
Panel Discussion
Panelists to be determined.

Colorado Ballroom
16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Functional Genomics and Systems Approaches
Registered attendees can view abstracts starting on 02/03/2019
Functional genomics, machine learning and data mining.

Colorado Ballroom
* Aravind Subramanian, Broad Institute, USA

Anna Greka, Harvard Medical School, USA
Toward Targeted, Mechanism-Based Therapies for Kidney Diseases

Lorenz M. Mayr, GE Healthcare Life Sciences, UK
Phenotypic Drug Discovery – The Move from High-Content to High-Impact Screening

Michael Bassik, Stanford University, USA
Development of High-Throughput Functional Genomics Tools to Study Drug Interactions and Mechanisms of Cellular Uptake

Francisca Vazquez, Broad Institute of Harvard and MIT, USA
Defining a Cancer Dependency Map

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom

THURSDAY, MARCH 7

07:00—08:00
Breakfast

Summit Gallery
08:00—09:00
Keynote Address
Registered attendees can view abstracts starting on 02/03/2019

Colorado Ballroom
* Monica Schenone, Pfizer Inc., USA

Benjamin F. Cravatt III, The Scripps Research Institute, USA
Activity-Based Proteomics – Protein and Ligand Discovery on a Global Scale

09:00—11:30
Compound Profiling and Repositioning
Registered attendees can view abstracts starting on 02/03/2019

Colorado Ballroom
* John Moffat, Genentech, Inc., USA

Christopher A. Lipinski, Chrstopher A. Lipinski PhD LLC, USA
High-Throughput in vivo Phenotypic Screening for Drug Repurposing: Discovery of MLR-1023, a Novel Insulin Sensitizer and Novel Lyn Kinase Activator with Clinical Proof-of-Concept

Coffee Break

Marco Prunotto, F. Hoffmann-La Roche Ltd., Switzerland
Molecular Information Phenotype-Based Drug Discovery: A 5 Year Journey

Bruce Posner, University of Texas Southwestern Medical Center, USA
Identifying Subtype-Selective Targets for NSCLC Using Phenotypic Screening and a Chemistry First Approach

Mo Mandegar, Tenaya Therapeutics, USA
Short Talk: Artificial Intelligence Accelerates Early-Stage Target and Drug Discovery

Christian T. Meyer, Vanderbilt University, USA
Short Talk: A Consensus Framework for Calculating Drug Synergy

11:30—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—18:45
Target Identification / Deconvolution
Registered attendees can view abstracts starting on 02/03/2019

Colorado Ballroom
* Ellen L. Berg, Eurofins DiscoverX, USA

Dyann F. Wirth, Harvard School of Public Health, USA
Target ID for Malaria

Bridget Wagner, Broad Institute, USA
The Importance of Phenotypic Screening in Identifying New Targets for Disease Therapeutics

Herbert Waldmann, Max Planck Institute for Molecular Physiology, Germany
Chemotype – Phenotype - Target

Heidi Greulich, Broad Institute of MIT and Harvard, USA
Short Talk: PDE3A Modulation for the Treatment of Cancer

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 02/03/2019

Colorado Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Peaks 1-3
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Peaks 1-3

FRIDAY, MARCH 8

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Merck & Co., Inc. Pfizer Inc.

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health
National Center for Advancing Translational Sciences (NCATS)

Grant No. 1R13TR002707-01

Funding for this conference was made possible (in part) by 1R13TR002707-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

Agilent

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Almirall, S.A.


Eurofins DiscoverX


Merck & Co., Inc.


Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676